Grenoble, France-based eCential Robotics, formerly known as Surgivisio, has announced its rebranding after receiving nearly 100 million euros in financing.
Introducing eCential Robotics
1 min read Premium comments
#ecentialrobotics#surgivisio
Founded in 2009, eCential Robotics designs and manufactures a system that brings together 2D/3D robotic imaging and surgical navigation. With its 60 patents and six registered trademarks, the company’s goal is to “reinforce the safety and accuracy of surgical procedures, while offering simplicity and speed of use.”
The eCential Robotics platform is a unified and open solution. As an open solution, surgeons can use the platform with their choice of manufacturer’s implants. Currently the platform employs an assortment of applications dedicated to spine surgery. Since its commercial launch in 2017, eight units have been sold and installed in France, Italy and Germany. Over one thousand surgeries have been performed using the platform. In the future, the platform will be “used for multiple bone surgery indications.”
eCential Robotics attributes the funding to the “support and trust of the company’s investors” and banks. It will use the equity, quasi-equity, and debt financing to support its industrial and commercial development. The financing allows the company to boost production capabilities and invest in product development. Commercially, eCential Robotics will use the financing to focus on its primary markets in France, Italy, and Germany. It then plans to slowly enter the North American market.
eCential Robotics President, CEO, and Founder Stéphane Lavallée commented, “With this financing of close to €100 million, unprecedented in the French medtech sector, eCential Robotics intends to become a major player in the transformation from traditional surgery to digital and robotic surgery, a field that is experiencing significant growth.”
Lavallée continued, “Our ambition is to become the market leader in digital surgery, imaging and robotics by offering hospitals and surgeons who use our products a secure solution for the best benefit of patients. This is how we intend to become essential to bone surgery operating rooms.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.